Nanobiotechnology, synthetic biology, and RNAi: patent portfolios for maximal near-term commercialization and commons for maximal long-term medical gain.
›
Linked as:Extract
Nanobiotechnology, synthetic biology, and RNAi: patent portfolios for maximal near-term commercialization and commons for maximal long-term medical gain.
No longer available (Autolink)
See the full content of this document
This document cites
- Lord Advocate v Corporation of Edinburgh
- Hughes v Grampian Country Food Group Ltd
- 2006/1/EC: Council Decision of 21 December 2005 appointing two Lithuanian members and three Lithuanian alternate members to the Committee of the Regions
- 2000/15/EC: Council Decision of 2 December 1999 concerning the conclusion of the Agreement for scientific and technological cooperation between the European Community and the Argentine Republic
- Federal Cases - Pfizer, Inc. v. Apotex, Inc.
